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Alzheimer’s disease is a complex and multifactorial condition regulated by both
genetics and lifestyle, which ultimately results in the accumulation of β-amyloid (Aβ) and
tau proteins in the brain, loss of gray matter, and neuronal death. This Special Issue, entitled
“Genetics of Alzheimer’s Disease,” focuses on genetic contributions to this debilitating
disease that may lead to better targeted therapeutics and diagnostics. This issue contains
six original research articles and two review papers that further our collective knowledge
of Alzheimer’s disease etiology and genetic risk factors underlying the disease.
Ibanez, Cruchaga [1] present a snapshot of current work in Alzheimer’s disease genet-
ics by contextualizing recent advances targeting immune responses from CD33 and TREM2
with more contemporary approaches investigating the amyloid cascade hypothesis. They
conclude that the molecular mechanisms modulating Alzheimer’s disease pathogenesis
should be considered broadly, and identifying additional genetic predisposition variants
may lead to better treatment through early prediction and diagnosis. Shaw, Katsumata [2]
found that limitations inherent with stringent multiple testing correction may mask the
ability to detect Alzheimer’s disease risk from complex copy number variations and genes
with coupled expression within immunomodulatory tyrosine-phosphorylated inhibitory
motifs (ITIMs) or activation motifs (ITAMs). They show that protein quantitative trait loci
associate with Alzheimer’s disease more frequently for genes encoding ITIM/ITAM family
members than non-ITIM/ITAM genes. Additionally, mitochondrial dysfunction may play
a role in Alzheimer’s disease, and differential transcription of the Translocase of Outer
Mitochondria Membrane 40 (TOMM40) gene is associated with Alzheimer’s disease in
postmortem brains [3].
Data mining is often used to identify novel disease-associated genetic risk factors for
Alzheimer’s disease. Huckvale, Hodgman [4] describe challenges with data mining on data
from the Alzheimer’s Disease Neuroimaging Initiative that may cause issues with various
machine learning algorithms. They describe significant feature correlation, where >90% of
all biomarkers are significantly correlated with at least one other biomarker in that dataset.
They recommend removing highly correlated features before performing large-scale data
analyses. Carpanini, Harwood [5] performed a targeted analysis of Alzheimer’s disease-
associated genes within the complement system in the IGAP dataset, and they confirmed
genetic associations for both CLU and CR1, but C1S was not significantly associated with
Alzheimer’s disease. They conclude that larger genome-wide association datasets and
long-read sequencing technologies may help better characterize the complement system
genetic landscape and its role in Alzheimer’s disease risk.
Peripheral blood biomarkers offer a promising, non-intrusive mechanism for early
Alzheimer’s disease diagnosis. Garofalo, Pandini [6] explore how non-coding RNA
molecules longer than 200 nucleotides are differentially expressed in peripheral tissue
of Alzheimer’s disease patients and may lead to noninvasive confirmatory targets or prog-
nostic biomarkers. Specifically, plasma BACE1-AS levels are differentially expressed in
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the pre-symptomatic phase, indicating long non-coding RNA molecules may be a viable
pre-symptomatic diagnostic target. Patel, Zhang [7] demonstrate that rare genetic variants
significantly impact gene expression and gene co-expression in Alzheimer’s disease, indi-
cating that set-based gene analyses are necessary to fully capture gene dynamics related
to disease progression. Those pathway-level analyses confirmed substantial immune and
inflammatory expression quantitative trait loci associated with Alzheimer’s disease, as
suggested in the review published in this Special Issue [1]. An association between immune
markers and Alzheimer’s disease is also proposed by van der Linden, De Witte [8], who
drew a correlation between levels of blood cytokines and growth factors and Alzheimer’s
disease genetic risk factors. They found that eight immune markers (three growth factors
and five cytokines) were downregulated by Alzheimer’s disease genetic risk factors, while
seven immune markers (five growth factors and three cytokines) were upregulated in the
blood when Alzheimer’s disease genetic risk factors were present.
The articles included in this Special Issue cover a range of topics and provide compre-
hensive insights to direct future Alzheimer’s disease genetics research. The growing num-
ber of pathways, genes, proteins, and molecules that appear to be involved in Alzheimer’s
disease is of special interest, which highlights the importance of analyzing Alzheimer’s
disease as a systemic disease and not just a neurological disorder. Findings in the blood
may serve as not only potential biomarkers or potential drug targets, but also help decipher
the pathobiology of the disease. We anticipate that this Special Issue will help researchers
search for additional genetic associations that will help refine our understanding of the
etiology of this complex disease.
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